Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 18Prostatic Neoplasms 6Carcinoma, Renal Cell 5Uveal Melanoma 4Sarcoma 4Histiocytoma, Malignant Fibrous 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Liposarcoma 2Leukemia 2Gastrointestinal Stromal Tumors 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma, Endometrioid 2Bone Neoplasms 2Vaginal Neoplasms 1Urogenital Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × CTLA-4 Antigen × Clear all
NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Completed
100 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡